A powerful new weapon in the fight against COVID-19 may soon be available for people who have been exposed to the virus. A recent clinical trial found that a daily antiviral pill called ensitrelvir significantly reduced the risk of catching COVID-19 among people living with someone who was infected.

The study, published in the New England Journal of Medicine, offers hope for a simple, at-home strategy to stop the virus from spreading within families. For millions of people who live with others, this could be a game-changer during future waves of the virus.

What the Study Found

Researchers led by Dr. Frederick Hayden from the University of Virginia enrolled nearly 2,400 household contacts of people who had tested positive for COVID-19. These contacts were at least 12 years old and had tested negative for the virus at the start of the study. They were randomly assigned to take either ensitrelvir or a placebo pill for a short period after their family member fell ill.

The results were striking. Among those who took at least one dose of the antiviral, only 2.9% developed COVID-19 within 10 days. In the placebo group, 9% became sick. That is a reduction of more than half.

Even when the researchers looked at all participants who were assigned to treatment—including those who never took the pill—the numbers still showed clear protection. In that broader group, 4.4% of those given ensitrelvir got COVID-19 compared with 10.2% in the placebo group.

Dr. Hayden called this a landmark finding. He told reporters that this is the first well-designed, large-scale study to prove that an easy-to-take oral medication can protect people who are exposed to COVID-19 in their own homes.

How This Affects You and Your Family

Think about the last time someone in your household came down with COVID-19. Maybe you tried to sleep in a separate room. Maybe you wore masks inside. Maybe you just hoped for the best. For many families, isolating a sick member is difficult or impossible, especially in smaller homes or when caring for children.

This study suggests that a short course of pills could offer an extra layer of protection. If approved in the United States, ensitrelvir could be prescribed to everyone in a household after one person tests positive. It would be taken once daily for a limited time, much like how Tamiflu is used for flu exposure.

Experts say this approach could be especially valuable for people who are at higher risk of severe illness, including older adults, people with obesity, smokers, and those with chronic health conditions. In this study, more than a third of household contacts had at least one of these risk factors.

Why This Matters Beyond the Home

The potential benefits extend far beyond individual households. Dr. Hayden pointed out that the same strategy could work in nursing homes, assisted living facilities, and other group settings where COVID-19 spreads quickly. In these environments, an exposed person might not have the option to isolate effectively. A preventive pill could help contain outbreaks before they start.

Previous attempts to find a preventive COVID-19 pill have failed. Two other well-known antivirals—Paxlovid and Lagevrio—were tested as preventive treatments after exposure but did not provide significant protection. That makes the success of ensitrelvir particularly noteworthy.

What Experts Say About Prevention Options Today

Right now, the main tools for preventing COVID-19 after exposure are vaccines, masks, and isolation. Vaccines remain highly effective at preventing severe illness, but they do not always stop infection entirely. Masks can reduce transmission but depend on consistent and correct use. Isolation works but is disruptive and not always possible.

Dr. Hayden noted that the flu has long had an effective preventive option in oseltamivir, better known as Tamiflu. For years, doctors have prescribed Tamiflu to family members of someone with the flu. A similar option for COVID-19 has been missing—until now.

It is important to remember that no single tool is perfect. The best protection against COVID-19 likely comes from combining vaccines, good ventilation, masking in high-risk settings, and now possibly preventive antivirals.

Safety and Side Effects

One of the most encouraging findings from the study was that ensitrelvir appeared to be safe and well-tolerated. Side effects occurred in about 15% of people in both the treatment group and the placebo group. That means the pill itself did not cause extra problems.

Unlike Paxlovid, which can cause a metallic taste in the mouth and stomach issues, ensitrelvir did not lead to more of these complaints than the placebo. This could make it easier for people to stick with the full course of treatment.

However, the researchers noted some important cautions. The study did not include pregnant women, so the safety of the drug during pregnancy is not yet known. Additionally, ensitrelvir is a moderate inhibitor of an enzyme called cytochrome P450 3A. This means it can interact with other medications that are broken down by the same enzyme. Anyone taking other drugs would need to check with their doctor or pharmacist before using ensitrelvir.

Study Limitations to Keep in Mind

No study is perfect, and this one had several limitations worth noting. The researchers did not track whether participants wore masks or took other precautions. These behaviors can influence how easily the virus spreads within a home. Also, about 19% of the people who first got sick in the household took antiviral medications themselves. That may have lowered their viral load and made them less contagious to begin with.

Another important detail: More than 98% of the household contacts in the study had antibodies against SARS-CoV-2, meaning they had either been vaccinated or infected before. This suggests the study tested the drug in a largely immune population, which is reflective of the current reality for most people. It is not clear whether the drug would work as well in people with no prior immunity.

Practical Takeaways for Readers

While ensitrelvir is not yet available in the United States, the manufacturer, Shionogi, has submitted it to the FDA for approval as a preventive treatment. A decision is expected by June. Here is what you should know right now:

• This is not a replacement for vaccination. Vaccines remain the best way to prevent severe illness, hospitalization, and death from COVID-19.
• If you are exposed to COVID-19, continue to follow current guidelines. Wear a high-quality mask, improve ventilation, and monitor for symptoms.
• Talk to your doctor about your risk factors. If you are older, obese, a smoker, or have a chronic condition, you may be a candidate for preventive treatments if they become available.
• Stay informed about new options. The approval of ensitrelvir could change how families and facilities handle COVID-19 exposures.
• Remember that timing matters. In the study, most household contacts started the medication within 48 hours of the first person showing symptoms. Quick action is key.

The Bottom Line

The COVID-19 pandemic has taught us that we need multiple layers of defense. Vaccines, masks, and testing have all played important roles. Now, a simple daily pill may join that toolkit. The study led by Dr. Hayden and his team provides strong evidence that ensitrelvir can cut the risk of infection by more than half when taken soon after exposure.

For families, this could mean fewer missed days of work and school. For nursing homes, it could mean fewer outbreaks. For individuals with health conditions, it could mean one more way to stay safe. As the FDA reviews the application, many experts are watching closely. If approved, ensitrelvir could become a standard part of how we respond to COVID-19 in the future.

Until then, the best advice remains the same: Stay up to date on your vaccines, test when you have symptoms or have been exposed, and take precautions to protect yourself and those around you.

Source: MedPage Today